Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
Key Highlights
- ➤Helus Pharma will present Phase 3 APPROACH topline results November 16, 2026
- ➤HLP003 is being evaluated as adjunctive treatment for major depressive disorder
- ➤HLP003 has FDA Breakthrough Therapy Designation
- ➤HLP004 remains in Phase 2 development for generalized anxiety disorder
NEW YORK and TORONTO, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder (“MDD”).
Please click here to access the webcast or visit the Events & Presentations page of Helus Pharma’s website. The archived webcast will be available on the Company’s website on the Events & Presentations page following the presentation.
Get started
Create a free account to read the full story.
